Urogen Pharma Ltd. (URGN)
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just reached a key level of support. URGN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue.
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.92 per share a year ago.
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.8 per share a year ago.
UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates
UroGen Pharma (URGN) is rated a Strong Buy, with a $33/share price target by end of 2026, driven by its proprietary RTGel technology. URGN's newly approved Zusduri targets a large bladder cancer market, offering a non-surgical alternative, with strong clinical results and significant revenue potential. Jelmyto's commercial success in a smaller market supports confidence in Zusduri's launch, with analysts projecting URGN to reach profitability by 2027.
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
UroGen Pharma Ltd. ( URGN ) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Christopher Degnan - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Raghuram Selvaraju - H.C.
